Generic pharma looking to create a new CDMO service businessSITUATION
- Leading specialty and generic pharma looking to spinoff a group of about 50 FTE that had expertise in small molecule and peptide formulations and manufacturing as well as advanced analytics
- They had also developed a novel drug delivery approach that can be applied to not onlyh small mol but also other advanced therapies that can deliver therapies to specific organs
- The changing mix of therapies from small mol, mabs to new therapeutics approaches drove the client to embark on this project
- What are the key gaps and unmet needs in drug formulations, analytics, drug delivery ?
- What is the size and segmentation of the markets in formulation services, analytics services and drug delivery
- What are some unique strengths of clients that gives them an advantage?
- How much business can I generate in the 5 year timeframe
- Outside in review: external interviews with pharma formulations dept heads, competitive reviews
- Inside out review: deep capability assessments of client
- Quant analysis: market sizing and segmentation
- Prioritization and workshops
- Developed a prioritization portfolio matrix of attractive market segments that fit with client capabilities
- Provided quant assessment of ROI; market penetration vs upfront investment requirements
- Recommendation: the market size and opportunities identified did not justify investment and hence client decided not to pursue the spinoff
